<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>8 Antibiotics - glycopeptides</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
		<link href="../sgStyles2.css" rel="stylesheet" type="text/css">
		<csimport user="../../../pharmTox.data/InDesignPackages/8 antibiotics/story_537.incd" occur="65">
			
		</csimport>
	</head>

<body>
<a id="top"></a>
<div id="text">
		<div id="sumbox">
		
			<div id="drugbox">
			
			</div>
		</div>
		<p class="titleSG">Glycopeptides</p>
		
		<input type="Button" value="Previous Page" onClick="history.go(-1)">
		
		<csobj csref="../../../pharmTox.data/InDesignPackages/8 antibiotics/story_537.incd" h="834" occur="65" t="Component" w="974" g="incopy_default" s="">
			<p class="ParBodytext"><span style="font-weight: bold; ">Vancomycin</span> is a glycopeptide with seven amino acids isolated from <span style="font-style: italic; ">Amycolatopsis </span>(<span style="font-style: italic; ">Nocardia </span>/ <span style="font-style: italic; ">Streptomyces</span>) <span style="font-style: italic; ">orientalis</span>. <span style="font-weight: bold; ">Teicoplanin</span> is similar. They are closely related to avoparcin which was used as a production enhancer and has now being withdrawn because of fears about cross resistance with vancomycin.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Acting outside the bacterial cell membrane, vancomycin blocks the transfer of the glycopeptide units from the carrier molecule to the growing polymer peptidoglycan (see penicillin diagram). It is therefore rapidly active.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Almost all Gram positive bacteria are sensitive to vancomycin. It is one of the few drugs effective against methicillin resistant <span style="font-style: italic; ">Staph. aureus</span> which is why there have been concerns about the possibility of resistance developing. There is complete cross resistance with avoparcin. Almost all Gram negative bacteria are resistant.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">High level resistance (<span style="font-style: italic; ">vanA</span> gene) transmitted on a transposon has been shown to pass between enterococci <span style="font-style: italic; ">in vitro</span>. There is a danger that these transposons could be passed to other pathogens such as <span style="font-style: italic; ">Staph. aureus</span>, although this has only been know to occur once in real life. The <span style="font-style: italic; ">vanC</span> gene, which confers low level resistance, is common in enterococcal chromosomes. A variety of soil bacteria, including some used as insecticides overseas, contain a very similar gene to <span style="font-style: italic; ">vanA</span>. Vancomycin intermediate <span style="font-style: italic; ">Staph. aureus</span> use a different mechanism - they have extra thick cell walls so that the drug does not get in easily.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Vancomycin is reserved in people as the last remaining effective treatment against MRSA (although resistance is starting to develop) and for life-threatening enterococcal infections.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Vancomycin must be given by iv infusion, teicoplanin can also be given im. They are not absorbed orally, and are only used orally in the treatment of antibiotic-associated pseudomembranous colitis caused by <span style="font-style: italic; ">Clostridium difficile</span>. Avoparcinâ€™s main use was the prevention of <span style="font-style: italic; ">Cl perfringens</span> necrotic enteritis in chickens and pigs - bacitracin or avilamycin are now used instead.</p>
			<p class="ParBodytext"></p>
			<p class="Parsubhead3">Politics</span></p>
			<p class="ParBodytext">Vancomycin is the drug of last resort for MRSA in people: it should be reserved for this use and <span style="font-weight: bold; ">should not be used in animals</span>. Avoparcin has been phased out as a growth promoter in NZ.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">New derivatives of vancomycin are being developed (eg, oritavancin) which circumvent current resistance problems. Do not expect to use them in animals.</p>
		</csobj>

		
		<table width="90%" border="0" align="center">
  <tr>
				<td class="titleSG"><a href="abIndex.html" class="aTitle">8 Antibiotics index</a></td>
			</tr>
</table>
		<br>
<table width="90%" border="0" align="center">
  <tr align="center">
    <td>    <a href="../../indexpharm.html"><img src="../../PharmBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../toxSite/indexTox.html"><img src="../../ToxBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../indexSG.html"><img src="../../SGbut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../lectureSite/indexLec.html"><img src="../../LecBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../formSite/Aform.html" target="_blank"><img src="../../FormBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../casesSite/indexCases.html"><img src="../../CaseBut.gif" width="100" height="21" border="0"></a></td>
  </tr>
</table>
<br>
<table width="90%" border="0" align="center" cellpadding="2" cellspacing="0">
  <tr bgcolor="#FFFFFF">
    <td width="50%" class="commonname"><img src="../../pharmBits/images/mulogo.gif" width="170" height="25"></td>
    <td width="50%" align="right" class="references"><div align="right">copyright
        Massey University</div>
    </td>
  </tr>
</table>
		<div id="gototop"><a href="#top"><b>top</b></a></div>

</div>
</body>
</html>
